-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Aligos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q4 2024.
- Aligos Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$20.6M, a 20.9% increase year-over-year.
- Aligos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$89.2M, a 1.17% decline year-over-year.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$89.2M, a 1.17% decline from 2023.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$88.1M, a 9.69% increase from 2022.
- Aligos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$97.6M, a 24% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)